IndiumV3, Main, Repository, bibRecord, 00EB54

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

Identifieur interne : 00EB54 ( Main/Repository ); précédent : 00EB53; suivant : 00EB55

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

Auteurs : RBID : Pascal:02-0266484

Descripteurs français

Pascal (Inist)
- Lymphome non hodgkinien, Résistance traitement, Rituximab, Anticorps monoclonal, Immunomodulateur, Anticytokine, Marquage radioisotopique, Yttrium, Immunoradiothérapie, Traitement, Ibritumomab tiuxétan, Dosimétrie, Homme, Antigène CD20, Yttrium 90.
Wicri :
- concept : Homme.

English descriptors

KwdEn :
- Anticytokine, Dosimetry, Human, Ibritumomab tiuxetan, Immunomodulator, Immunoradiotherapy, Monoclonal antibody, Non Hodgkin lymphoma, Radiolabelling, Rituximab, Treatment, Treatment resistance, Yttrium.

Abstract

BACKGROUND. Zevalin consists of a murine anti-CD20 monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates indium-111(¹¹¹In) for imaging and dosimetry and yttrium-90 (⁹⁰Y) for radioimmunotherapy (RIT). Previous trials involving rituximab-naive patients have demonstrated excellent targeting of Zevalin to CD20+ B-cell non-Hodgkin lymphoma with minimal uptake in normal organs. The purpose of this trial was to perform ¹¹¹ In-Zevalin imaging in patients with rituximab-refractory tumors to determine normal organ dosimetry. METHODS. Twenty-seven patients were given an imaging dose of 5 mCi (185 MBq) ¹¹¹ In-Zevalin on Day 0, evaluated with dosimetry, and then given a therapeutic dose of 0.4 mCi/kg (15 MBq/kg) ⁹⁰Y-Zevalin on Day 7. Both Zevalin doses were preceded by an infusion of 250 mg/m² rituximab to clear peripheral B cells and improve Zevalin biodistribution. Residence times for ⁹⁰Y in blood and major organs were estimated from ¹¹¹In biodistribution, and the MIRDOSE3 computer software program was used to calculate absorbed radiation doses to organs and red marrow. RESULTS. Median estimated absorbed radiation doses from ⁹⁰Y-Zevalin were 8.1 Gray (Gy) (range, 4.2-23.0 Gy) to the spleen, 5.1 Gy (range, 2.6-12.0 Gy) to the liver, 2.0 Gy (range, 1.4-5.3 Gy) to the lungs, 0.22 Gy (range, < 0.01-0.66 Gy) to the kidneys, and 0.74 Gy (range, 0.29-1.2 Gy) to the red marrow. These results are consistent with those from earlier Zevalin trials in rituximab-naïve patients. Hematologic toxicity was manageable and did not correlate with estimates of red marrow or total-body absorbed radiation dose. CONCLUSIONS. Zevalin treatment of rituximab-refractory follicular NHL patients at 0.4 mCi/kg resulted in acceptable estimates of absorbed radiation dose to organs, similar to those observed in other Zevalin-treated populations.

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 00F369

Links to Exploration step

Pascal:02-0266484

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma</title>
<author><name sortKey="Wiseman, Gregory A" uniqKey="Wiseman G">Gregory A. Wiseman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Nuclear Medicine, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rochester, Minnesota</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leigh, Bryan" uniqKey="Leigh B">Bryan Leigh</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>IDEC Pharmaceuticals Corporation</s1>
<s2>San Diego, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Idaho</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Erwin, William D" uniqKey="Erwin W">William D. Erwin</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Northwestern University and Robert H. Lurie Cancer Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, Illinois</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lamonica, Dominick" uniqKey="Lamonica D">Dominick Lamonica</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Nuclear Medicine, Roswell Park Cancer Center</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Buffalo, New York</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kornmehl, Ellen" uniqKey="Kornmehl E">Ellen Kornmehl</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Radiation Oncology, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Boston, Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Spies, Stewart M" uniqKey="Spies S">Stewart M. Spies</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Radiology, Northwestern University and Robert H. Lurie Cancer Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Chicago, Illinois</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Silverman, Daniel H S" uniqKey="Silverman D">Daniel H. S. Silverman</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Nuclear Medicine, Ahmanson Biochemical Imaging Center, UCLA Medical Center</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Los Angeles, California</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Witzig, Thomas E" uniqKey="Witzig T">Thomas E. Witzig</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Nuclear Medicine, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Rochester, Minnesota</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sparks, Richard B" uniqKey="Sparks R">Richard B. Sparks</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Oak Ridge Associated Universities</s1>
<s2>Oak Ridge, Tennessee</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Oak Ridge Associated Universities</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="White, Christine A" uniqKey="White C">Christine A. White</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>IDEC Pharmaceuticals Corporation</s1>
<s2>San Diego, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Idaho</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="inist">02-0266484</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0266484 INIST</idno>
<idno type="RBID">Pascal:02-0266484</idno>
<idno type="wicri:Area/Main/Corpus">00F369</idno>
<idno type="wicri:Area/Main/Repository">00EB54</idno>
</publicationStmt>
<seriesStmt><idno type="ISSN">0008-543X</idno>
<title level="j" type="abbreviated">Cancer</title>
<title level="j" type="main">Cancer</title>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anticytokine</term>
<term>Dosimetry</term>
<term>Human</term>
<term>Ibritumomab tiuxetan</term>
<term>Immunomodulator</term>
<term>Immunoradiotherapy</term>
<term>Monoclonal antibody</term>
<term>Non Hodgkin lymphoma</term>
<term>Radiolabelling</term>
<term>Rituximab</term>
<term>Treatment</term>
<term>Treatment resistance</term>
<term>Yttrium</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphome non hodgkinien</term>
<term>Résistance traitement</term>
<term>Rituximab</term>
<term>Anticorps monoclonal</term>
<term>Immunomodulateur</term>
<term>Anticytokine</term>
<term>Marquage radioisotopique</term>
<term>Yttrium</term>
<term>Immunoradiothérapie</term>
<term>Traitement</term>
<term>Ibritumomab tiuxétan</term>
<term>Dosimétrie</term>
<term>Homme</term>
<term>Antigène CD20</term>
<term>Yttrium 90</term>
</keywords>
<keywords scheme="Wicri" type="concept" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND. Zevalin consists of a murine anti-CD20 monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates indium-111(<sup>111</sup>
In) for imaging and dosimetry and yttrium-90 (<sup>90</sup>
Y) for radioimmunotherapy (RIT). Previous trials involving rituximab-naive patients have demonstrated excellent targeting of Zevalin to CD20+ B-cell non-Hodgkin lymphoma with minimal uptake in normal organs. The purpose of this trial was to perform <sup>111</sup>
 In-Zevalin imaging in patients with rituximab-refractory tumors to determine normal organ dosimetry. METHODS. Twenty-seven patients were given an imaging dose of 5 mCi (185 MBq) <sup>111</sup>
 In-Zevalin on Day 0, evaluated with dosimetry, and then given a therapeutic dose of 0.4 mCi/kg (15 MBq/kg) <sup>90</sup>
Y-Zevalin on Day 7. Both Zevalin doses were preceded by an infusion of 250 mg/m<sup>2</sup>
 rituximab to clear peripheral B cells and improve Zevalin biodistribution. Residence times for <sup>90</sup>
Y in blood and major organs were estimated from <sup>111</sup>
In biodistribution, and the MIRDOSE3 computer software program was used to calculate absorbed radiation doses to organs and red marrow. RESULTS. Median estimated absorbed radiation doses from <sup>90</sup>
Y-Zevalin were 8.1 Gray (Gy) (range, 4.2-23.0 Gy) to the spleen, 5.1 Gy (range, 2.6-12.0 Gy) to the liver, 2.0 Gy (range, 1.4-5.3 Gy) to the lungs, 0.22 Gy (range, < 0.01-0.66 Gy) to the kidneys, and 0.74 Gy (range, 0.29-1.2 Gy) to the red marrow. These results are consistent with those from earlier Zevalin trials in rituximab-naïve patients. Hematologic toxicity was manageable and did not correlate with estimates of red marrow or total-body absorbed radiation dose. CONCLUSIONS. Zevalin treatment of rituximab-refractory follicular NHL patients at 0.4 mCi/kg resulted in acceptable estimates of absorbed radiation dose to organs, similar to those observed in other Zevalin-treated populations.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0008-543X</s0>
</fA01>
<fA02 i1="01"><s0>CANCAR</s0>
</fA02>
<fA03 i2="1"><s0>Cancer</s0>
</fA03>
<fA05><s2>94</s2>
</fA05>
<fA06><s2>4</s2>
<s3>SUP</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Eighth Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, New Jersey, October 12-14, 2000</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>WISEMAN (Gregory A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LEIGH (Bryan)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ERWIN (William D.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LAMONICA (Dominick)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>KORNMEHL (Ellen)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SPIES (Stewart M.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SILVERMAN (Daniel H. S.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WITZIG (Thomas E.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>SPARKS (Richard B.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>WHITE (Christine A.)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Nuclear Medicine, Mayo Clinic and Mayo Foundation</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>IDEC Pharmaceuticals Corporation</s1>
<s2>San Diego, California</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Radiology, Northwestern University and Robert H. Lurie Cancer Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Nuclear Medicine, Roswell Park Cancer Center</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Radiation Oncology, Harvard Medical School</s1>
<s2>Boston, Massachusetts</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Nuclear Medicine, Ahmanson Biochemical Imaging Center, UCLA Medical Center</s1>
<s2>Los Angeles, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Oak Ridge Associated Universities</s1>
<s2>Oak Ridge, Tennessee</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>1349-1357</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2701</s2>
<s5>354000100191080210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0266484</s0>
</fA47>
<fA60><s1>P</s1>
<s2>C</s2>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Cancer</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>BACKGROUND. Zevalin consists of a murine anti-CD20 monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates indium-111(<sup>111</sup>
In) for imaging and dosimetry and yttrium-90 (<sup>90</sup>
Y) for radioimmunotherapy (RIT). Previous trials involving rituximab-naive patients have demonstrated excellent targeting of Zevalin to CD20+ B-cell non-Hodgkin lymphoma with minimal uptake in normal organs. The purpose of this trial was to perform <sup>111</sup>
 In-Zevalin imaging in patients with rituximab-refractory tumors to determine normal organ dosimetry. METHODS. Twenty-seven patients were given an imaging dose of 5 mCi (185 MBq) <sup>111</sup>
 In-Zevalin on Day 0, evaluated with dosimetry, and then given a therapeutic dose of 0.4 mCi/kg (15 MBq/kg) <sup>90</sup>
Y-Zevalin on Day 7. Both Zevalin doses were preceded by an infusion of 250 mg/m<sup>2</sup>
 rituximab to clear peripheral B cells and improve Zevalin biodistribution. Residence times for <sup>90</sup>
Y in blood and major organs were estimated from <sup>111</sup>
In biodistribution, and the MIRDOSE3 computer software program was used to calculate absorbed radiation doses to organs and red marrow. RESULTS. Median estimated absorbed radiation doses from <sup>90</sup>
Y-Zevalin were 8.1 Gray (Gy) (range, 4.2-23.0 Gy) to the spleen, 5.1 Gy (range, 2.6-12.0 Gy) to the liver, 2.0 Gy (range, 1.4-5.3 Gy) to the lungs, 0.22 Gy (range, < 0.01-0.66 Gy) to the kidneys, and 0.74 Gy (range, 0.29-1.2 Gy) to the red marrow. These results are consistent with those from earlier Zevalin trials in rituximab-naïve patients. Hematologic toxicity was manageable and did not correlate with estimates of red marrow or total-body absorbed radiation dose. CONCLUSIONS. Zevalin treatment of rituximab-refractory follicular NHL patients at 0.4 mCi/kg resulted in acceptable estimates of absorbed radiation dose to organs, similar to those observed in other Zevalin-treated populations.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B26J</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Résistance traitement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Treatment resistance</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Resistencia tratamiento</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Rituximab</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Anticorps monoclonal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Monoclonal antibody</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Anticuerpo monoclonal</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Immunomodulateur</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Immunomodulator</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Inmunomodulador</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Anticytokine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Anticytokine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Anticitoquina</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Marquage radioisotopique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Radiolabelling</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Marcación radioisotópica</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Yttrium</s0>
<s2>NC</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Yttrium</s0>
<s2>NC</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Ytrio</s0>
<s2>NC</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Immunoradiothérapie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Immunoradiotherapy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Inmunoradioterapia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Ibritumomab tiuxétan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Ibritumomab tiuxetan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Ibritumomab tiuxetán</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Dosimétrie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Dosimetry</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Dosimetría</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Homme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Human</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Hombre</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Antigène CD20</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Yttrium 90</s0>
<s4>INC</s4>
<s5>90</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Lymphoprolifératif syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Radiothérapie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Radiotherapy</s0>
<s5>61</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Radioterapia</s0>
<s5>61</s5>
</fC07>
<fN21><s1>154</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
<pR><fA30 i1="01" i2="1" l="ENG"><s1>Conference on Radioimmunodetection and Radioimmunotherapy of Cancer</s1>
<s2>8</s2>
<s3>Princeton, New Jersey USA</s3>
<s4>2000-10-12</s4>
</fA30>
</pR>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV3/Data/Main/Repository

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00EB54 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Repository/biblio.hfd -nk 00EB54 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV3
   |flux=    Main
   |étape=   Repository
   |type=    RBID
   |clé=     Pascal:02-0266484
   |texte=   Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma
}}

This area was generated with Dilib version V0.5.77.
Data generation: Mon Jun 9 10:27:54 2014. Site generation: Thu Mar 7 16:19:59 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri